Latest Sanofi Press Releases and News | Sanofi
WEBSep 10, 2024 · Stay informed with the latest Sanofi press releases and news updates. Discover new developments in healthcare and pharmaceuticals with Sanofi.
Sanofi wins US approval for multiple myeloma drug in newly …
WEB1 day ago · U.S. Food and Drug Administration. Follow. Sept 20 - Sanofi (SASY.PA) won approval for the use of a drug combination with its Sarclisa infusion to treat certain types of newly diagnosed multiple ...
Sanofi's tolebrutinib drug delays progressive MS by 31% in trial
WEB2 days ago · FRANKFURT, Sept 20 (Reuters) - Sanofi (SASY.PA) said on Friday that its multiple sclerosis drug candidate was shown to delay worsening of a progressive form of the disease by 31%, as the French ...
Sanofi eyes approval after MS therapy slows disease progression …
WEB2 days ago · SNY. Sanofi is eyeing global regulatory approval for tolebrutinib after releasing positive Phase III data in non-relapsing secondary progressive multiple sclerosis (MS), The results from the ...
Sanofi pushes ahead with €20bn consumer healthcare spin-off
WEBJun 2, 2024 · The move makes Sanofi the latest Big Pharma company to seek to separate low-margin, consumer businesses from divisions focused on innovative new medicines that offer higher returns.
Sanofi wins US approval for multiple myeloma drug in newly …
WEB2 days ago · -The U.S. Food and Drug Administration said on Friday it has approved the use of a drug combination along with Sanofi's Sarclisa infusion as a treatment for certain types of newly diagnosed multiple myeloma patients. Sarclisa has previously been approved for use as a fallback therapy for certain cases of multiple myeloma after standard treatments have failed. The French drugmaker, a market ...
Sanofi Pipeline Transformation to Accelerate Growth Driven by …
WEBDec 7, 2002 · Sanofi’s R&D will lead to a 50% increase in the number of Phase 3 studies between 2023 and 2025, creating the greatest pipeline momentum in Sanofi’s history. The company’s commitment to R&D will also support an expected 25 mid- to late-stage read-outs and up to 19 regulatory submissions for its pharma assets in the next two years.
Sanofi US News
WEB6 days ago · The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2023. Other than as ...
Press Room - Sanofi US News
WEBApr 26, 2024 · Sanofi US News. New data presented at ATS demonstrate Sanofi’s leadership in advancing potential new therapies for patients with immune-mediated respiratory diseases.
Press Room - Sanofi US News
WEBUpdated as of October 26, 2023. There has been unprecedented demand for Beyfortus™ (nirsevimab-alip). For the first time in history, health care providers are able to help protect an extraordinary number of infants against respiratory syncytial virus (RSV) disease.
Skip to content